June 23, 2026 a 09:00 pm

CRL: Analysts Ratings - Charles River Laboratories International, Inc.

Historical Stock Grades

Reviewing analyst ratings over the past months for CRL reveals a trend toward "Buy" ratings, with a notable rise in strong buys as of June 2026. The distribution suggests a dominant confidence among analysts, though some caution is evidenced by sustained "Hold" positions.

Recommendation	Count	Score
Strong Buy	4
Buy	10
Hold	3
Sell	0
Strong Sell	1

Sentiment Development

The sentiment surrounding CRL has evolved over recent months, reflecting an increase in analyst confidence. Notably, "Strong Buy" recommendations have increased, and there's been a decrease in "Hold" ratings, suggesting a shift towards more bullish expectations.

• Increase in "Strong Buy" recommendations from 1 in February 2026 to 4 in June 2026.
• Fluctuations in "Hold" ratings, peaking to 15 in June 2025 but reducing to 3 by June 2026.
• Consistent reduction in overall neutral or bearish sentiment, as evidenced by zero "Sell" recommendations by June 2026.

Percentage Trends

Analysts' perspectives have gradually tilted toward a more positive outlook for CRL. There's a clear reallocation from "Hold" to "Buy" and "Strong Buy," indicating growing confidence in the company’s performance. Analysis over the past year highlights these notable shifts:

• By June 2026, "Buy" and "Strong Buy" combined account for the majority rating with approximately 70% of recommendations.
• A decline in "Hold" ratings from 16 in April 2025 to just 3 in June 2026 solidifies the positive trend.
• This change points to a gradual but steady increase in conviction among analysts for the stock's potential.

Latest Analyst Recommendations

Recent analyst activities show upgrades and maintained positive ratings for CRL. The momentum is noticeably optimistic, reflecting either an improvement in fundamentals or favorable conditions in the CRO sector.

Date	New Recommendation	Last Recommendation	Publisher
2026-06-17	Overweight	Equal Weight	Morgan Stanley
2026-05-29	Outperform	Hold	CLSA
2026-05-08	Overweight	Overweight	Barclays
2026-05-08	Outperform	Outperform	Evercore ISI Group
2026-04-14	Overweight	Overweight	Barclays

Analyst Recommendations with Change of Opinion

Upgrades have been a prominent theme, indicating a shift in analyst sentiments toward more optimistic forecasts. This pattern highlights external and internal factors driving increased confidence.

Date	New Recommendation	Last Recommendation	Publisher
2026-06-17	Overweight	Equal Weight	Morgan Stanley
2026-05-29	Outperform	Hold	CLSA
2025-11-06	Outperform	Neutral	Baird
2025-10-06	Outperform	Market Perform	William Blair
2025-10-02	Overweight	Equal Weight	Barclays

Interpretation

The increasing analyst recommendations towards "Buy" and "Strong Buy" statuses for CRL indicate a perceived strengthening of the company's fundamentals, possibly tied to sector dynamics or strategic company moves. While there appears to be a gradual build-up of confidence among analysts, it's crucial for investors to monitor potential shifts in the sector and any forthcoming economic headwinds. The overall stability of analyst opinion seems robust, with occasional fluctuations minimally affecting overall sentiment.

Conclusion

Charles River Laboratories International, Inc. is witnessing a positive shift in analyst sentiment with growing favorability in ratings. The company stands at a converging point of strategic initiatives and favorable industry position with analysts showcasing increased trust. Despite potential risks linked with macroeconomic shifts impacting laboratory demand, the prevailing sentiment backed by recent developments across its core operational segments holds promise for future growth. Investors should consider the analyzed transformations when making informed decisions regarding CRL stock.